Top-News
Biotechnologie Deutschland

Immatics NV Aktie

Aktie
WKN:  A2P72S ISIN:  NL0015285941 US-Symbol:  IMTX
6,865 €
-0,21 €
-2,97%
13.12.24
Handeln Depot/Watchlist
Aktienanzahl *
103,05 Mio.
Marktkapitalisierung *
790,37 Mio. €
Streubesitz
71,40%
Index-Zugehörigkeit
-
IR-Website
zur Website
*Stand: 02.07.2024

Immatics NV News

20.11.24 - Der Aktionär
Immatics: Deutsche Biotech‑Hoffnung unter Druck
18.11.24 - GlobeNewswire
Immatics Announces Third Quarter 2024 Financial Results, Business Update and First Clinical Data on TCER® IMA402 Targeting PRAME
The Company will now target five major cancer types with its four clinically active compounds across both TCR-T cell therapies and TCR-based Bispecifics
08.11.24 - GlobeNewswire
Immatics Announces Multiple Presentations at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) on TCR-T Therapy Candidates Targeting PRAME
Two oral presentations and multiple posters on clinical and preclinical-​stage candidates to be presented at SITC, demonstrating the strength of Immatics’ TCR-T PRAME franchise ...
11.10.24 - GlobeNewswire
Immatics Announces Pricing of $150 Million Public Offering
H ouston, Texas and Tuebingen, Germany, October 10, 2024 – Immatics N.V. (NASDAQ: IMTX, “Immatics”), a clinical-​stage biopharmaceutical company active in the discovery and ...
10.10.24 - GlobeNewswire
Immatics Announces Proposed $150 Million Public Offering
Houston, Texas and Tuebingen, Germany, October 10, 2024 – Immatics N.V. (NASDAQ: IMTX, “Immatics”), a clinical-​stage biopharmaceutical company active in the discovery and ...
10.10.24 - GlobeNewswire
Immatics Announces Updated Phase 1b Clinical Data on ACTengine® IMA203 TCR-T Targeting PRAME in Melanoma Patients and Provides Update on Upcoming SUPRAME Phase 3 Trial
Company to host conference call and webcast today, October 10, at 9:00 am EDT/3:00 pm CEST
04.10.24 - GlobeNewswire
Immatics Announces Upcoming Oral and Poster Presentations at the Society for Immunotherapy of Cancer Annual Meeting 2024
Houston, Texas and Tuebingen, Germany, October 4, 2024 – Immatics N.V. (NASDAQ: IMTX, “Immatics” or the “Company”), a clinical-​stage biopharmaceutical company active in the ...
16.09.24 - GlobeNewswire
Immatics Presents Clinical Proof-of-Concept Data from Ongoing Phase 1 Dose Escalation Trial with TCR Bispecific Molecule TCER® IMA401 Targeting MAGEA4/8 at ESMO 2024 and Provides Development Update
TCER® IMA401 is a novel, next-​generation, half-life extended bispecific T cell engager directed against an HLA-A*02-presented peptide derived from MAGEA4 and MAGEA8 with high ...
06.09.24 - GlobeNewswire
Immatics Announces Upcoming Oral Presentation at the Society for Melanoma Research Congress 2024
Houston, Texas and Tuebingen, Germany, September 06, 2024 – Immatics N.V. (NASDAQ: IMTX, “Immatics” or the “Company”), a clinical-​stage biopharmaceutical company active in the ...
13.08.24 - GlobeNewswire
Immatics Announces Second Quarter 2024 Financial Results and Business Update
Clinical data from May 2024 on ACTengine® IMA203 targeting PRAME in 30 heavily pre-​treated metastatic melanoma patients at RP2D: 55% confirmed objective response rate, ...
31.07.24 - GlobeNewswire
Immatics Appoints Alise Reicin to Board of Directors
Houston, Texas and Tuebingen, Germany, July 31, 2024 – Immatics N.V. (NASDAQ: IMTX, “Immatics” or the “Company”), a clinical-​stage biopharmaceutical company active in the ...
18.07.24 - GlobeNewswire
Immatics Announces Upcoming Oral Presentation at ESMO Congress 2024
Houston, Texas and Tuebingen, Germany, July 18, 2024 – Immatics N.V. (NASDAQ: IMTX, “Immatics”), a clinical-​stage biopharmaceutical company active in the discovery and ...
22.05.24 - Der Aktionär
Biotech‑Hoffnung Immatics: "Einzigartige Positionierung" (Teil 2)
22.05.24 - Der Aktionär
Biotech‑Hoffnung Immatics: "Diese Daten bestätigen das große Potenzial" (Teil 1)
14.05.24 - GlobeNewswire
Immatics Announces First Quarter 2024 Financial Results and Business Update
Company Provides Clinical Data Update from Ongoing Phase 1 Clinical Trial with ACTengine® IMA203 TCR-T Targeting PRAME
21.03.24 - GlobeNewswire
Immatics Announces Full Year 2023 Financial Results and Corporate Update
Interim clinical data update on ACTengine® IMA203 GEN1 (PRAME) in melanoma at RP2D in November 2023: 50% confirmed objective response rate with median duration of ...
18.01.24 - GlobeNewswire
Immatics Announces Pricing of $175 Million Public Offering
Houston, Texas and Tuebingen, Germany, January 17, 2024 – Immatics N.V. (NASDAQ: IMTX, “Immatics”), a clinical-​stage biopharmaceutical company active in the discovery and ...
17.01.24 - GlobeNewswire
Immatics Announces Proposed Public Offering
Houston, Texas and Tuebingen, Germany, January 17, 2024 – Immatics N.V. (NASDAQ: IMTX, “Immatics”), a clinical-​stage biopharmaceutical company active in the discovery and ...
16.01.24 - DerFinanzinvestor
Viel Bewegung im Pharmasegment - Cardiol Therapeutics, Moderna, MorphoSys Aktie
Der DAX "verkeilt" sich seit Jahresanfang 2023 auf hohem Niveau und eine nächste Ausbruchbewegung steht damit kurz bevor. Bereits ausgebrochen sind viele Aktien aus der ...
16.01.24 - PR Newswire
DISCO Pharmaceuticals launches as the surfaceome company with EUR 20 Million in Seed Financing
DISCO Pharmaceuticals launches as the surfaceome company with EUR 20 Million in Seed Financing PR Newswire

Newssuche

Videos

newspaper
13.12.24
TRADING Insights Webinar vom 12.12.24
Themen: Aktienmarkt-​Entwicklung, Soft-​Commodities, wie Baumwolle, Kakao, Orangensaft, aber auch die ... Mehr »